Letermovir for Prophylaxis and Pre-emptive Therapy of Cytomegalovirus Infection in Paediatric Allogeneic Haematopoietic Cell Transplant Patients-Reference-Cited by-同舟云学术

Letermovir for Prophylaxis and Pre-emptive Therapy of Cytomegalovirus Infection in Paediatric Allogeneic Haematopoietic Cell Transplant Patients

Published:2022-12-27 Issue:2 Volume:25 Page:225-232
ISSN:1174-5878
Container-title:Pediatric Drugs
language:en
Short-container-title:Pediatr Drugs

Author:

Körholz Katharina F.,Füller Miriam A.,Hennies Marc,Holterhus Malcolm,Hagedorn Susanne,Ahlmann Martina,Thorer Heike,Burkhardt Birgit,Groll Andreas H.^ORCID

Funder

Universitätsklinikum Münster

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pediatrics, Perinatology and Child Health

Link

https://link.springer.com/content/pdf/10.1007/s40272-022-00547-6.pdf

Reference35 articles.

1. Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, Hubacek P, Navarro D, Cordonnier C, Ward KN. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19:e260–72. https://doi.org/10.1016/s1473-3099(19)30107-0.

2. Solano C, Vázquez L, Giménez E, de la Cámara R, Albert E, Rovira M, Espigado I, Calvo CM, López-Jiménez J, Suárez-Lledó M, et al. Cytomegalovirus DNAemia and risk of mortality in allogeneic hematopoietic stem cell transplantation: analysis from the Spanish hematopoietic transplantation and cell therapy group. Am J Transplant. 2021;21:258–71. https://doi.org/10.1111/ajt.16147.

3. Teira P, Battiwalla M, Ramanathan M, Barrett AJ, Ahn KW, Chen M, Green JS, Saad A, Antin JH, Savani BN, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127:2427–38. https://doi.org/10.1182/blood-2015-11-679639.

4. Jang JE, Hyun SY, Kim YD, Yoon SH, Hwang DY, Kim SJ, Kim Y, Kim JS, Cheong JW, Min YH. Risk factors for progression from cytomegalovirus viremia to cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18:881–6. https://doi.org/10.1016/j.bbmt.2011.10.037.

5. Green ML, Leisenring W, Xie H, Mast TC, Cui Y, Sandmaier BM, Sorror ML, Goyal S, Özkök S, Yi J, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3:e119-127. https://doi.org/10.1016/s2352-3026(15)00289-6.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Letermovir for Cytomegalovirus infection in pediatric patients undergoing allogenic hematopoietic stem cell transplantation: a real-life study by the Infectious Diseases Working Group of Italian Association of Pediatric Hematology-Oncology (AIEOP);Bone Marrow Transplantation;2024-01-25

2. Letermovir for CMV Prophylaxis in Very High-Risk Pediatric Hematopoietic Stem Cell Transplantation Recipients for Inborn Errors of Immunity;Journal of Clinical Immunology;2023-12-20

3. Virus infections after allogeneic stem cell transplantation in children. Review;EJC Paediatric Oncology;2023-12

4. CMV prevention strategies in allogeneic hematopoietic cell transplantation; the role of prophylaxis and pre‐emptive monitoring in the era of letermovir;Transplant Infectious Disease;2023-10-20

5. New Treatment Options for Refractory/Resistant CMV Infection;Transplant International;2023-10-12